Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down – Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped down prior to trading on Monday . The stock had previously closed at $11.45, but opened at $10.70. Dyne Therapeutics shares last traded at $10.29, with a volume of 114,542 shares traded.

Analysts Set New Price Targets

A number of research firms recently issued reports on DYN. Scotiabank began coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. BMO Capital Markets started coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Stock Performance

The stock’s 50-day simple moving average is $13.27 and its two-hundred day simple moving average is $23.39. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -2.82 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 6,237 shares of company stock worth $77,760 in the last ninety days. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics in the third quarter worth about $36,000. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics during the fourth quarter worth about $50,000. KBC Group NV boosted its holdings in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares in the last quarter. Finally, Summit Investment Advisors Inc. grew its stake in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after purchasing an additional 721 shares during the period. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.